Palisade Bio, Inc. PALI
0.94 USD -0.07 (-6.72%)
Regular-session close
0.92 -0.02 -2.35%
After hours · Nov 18, 6:32 PM ET
0.9393 Day range 1.01
0.9393 52-week range 2.86
- YTD
- -59.91%
- 1 year
- -54.49%
News
benzinga.com Palisade Bio Analysts Slash Their Forecasts After Q3 Results Palisade Bio, Inc. (NASDAQ:PALI) reported a wider-than-expected loss for the third quarter on Tuesday.
benzinga.com Palisade Bio Analysts Slash Their Forecasts After Q3 Results Palisade Bio missed Q3 loss estimates at 7¢/share. Shares rose 3.1% as analysts cut price targets; ASCENTRA trials advance.benzinga.com Piper Sandler Maintains Overweight on Palisade Bio, Lowers Price Target to $16 Piper Sandler analyst Yasmeen Rahimi maintains Palisade Bio (NASDAQ:PALI) with a Overweight and lowers the price target from $25 to $16.
benzinga.com HC Wainwright & Co. Maintains Buy on Palisade Bio, Lowers Price Target to $5 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Palisade Bio (NASDAQ:PALI) with a Buy and lowers the price target from $7 to $5.
benzinga.com Palisade Bio Q3 EPS $(0.07) Misses $(0.06) Estimate Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 81.58 percent increase over losses of…
globenewswire.com Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027 FDA Clearance Received for Phase 2a ASCENTRA-CD Trial; Initiation of Enrollment Targeted for Q1 2027 New…
seekingalpha.com Palisade: Initiating 'Buy' On PALI-2108 UC Study Start And Differentiated PDE4 Inhibitor I initiate Palisade Bio with a "Buy" rating, driven by its differentiated oral PDE4 inhibitor prodrug PALI-2108 targeting inflammatory bowel diseases. PALI's phase 2b ASCENTRA-UC trial for ulcerative…benzinga.com Palisade Bio Doses First Patient In Its ASCENTRA-UC Phase 2b Clinical Trial Evaluating PALI-2108 In ~204 Patients With Moderately To Severely Active Ulcerative Colitis; 12-Week Topline Results Expected In Q4 2027 PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability29 of…
globenewswire.com Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerabilitybenzinga.com Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated linical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain. The…
globenewswire.com Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026 Five-patient Phase 1b Crohn's disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days
globenewswire.com Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026 Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 development Two…
defenseworld.net Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.83 According to Analysts Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) has been given a consensus rating of "Buy" by the ten ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research…
globenewswire.com Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn's disease
defenseworld.net Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s Palisade Bio (NASDAQ: PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn's disease after completing its Phase I program. Chief…
marketbeat.com Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's Palisade Bio NASDAQ: PALI said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn's disease after completing its Phase I program.
globenewswire.com Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active…
globenewswire.com Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn's disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response)…
globenewswire.com Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a…
seekingalpha.com Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com Palisade Bio to Participate in Upcoming Investor Conferences Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for…
defenseworld.net Brokerages Set Palisade Bio, Inc. (NASDAQ:PALI) Price Target at $9.00 Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) has received a consensus rating of "Buy" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst…
globenewswire.com Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first…
benzinga.com Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2 Oppenheimer on Thursday initiated coverage of Palisade Bio Inc. (NASDAQ:PALI) , saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease…
globenewswire.com Palisade Bio to Participate in the Leerink Partners Therapeutics Forum Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage…
